

1 **Original Research Article**

2 **Far beyond the IgE Insights into the clinical profile**
3 **of allergic patients with selective IgE deficiency,**
4 **urticarial vasculitis, allergic pharyngitis, and**
5 **perennial allergic conjunctivitis**

37 **ABSTRACT**

38

Aims: Medical literature defines the diagnosis of “selective IgE deficiency” (slgEd) as the individuals able to produce, at normal amounts, all antibodies’ classes, and subclasses, with exception of the IgE, which is not found by the laboratory detection method (usually below 2.0 kIU/L). Patients with slgEd may present non—IgE-mediated allergies/hypersensitivities, turning them into ideal subjects to study these conditions.

Study design: To evaluate by a retrospective chart review the allergic conditions of the slgEd cohort population attended at an Allergy and Immunology medical facility.

Place and Duration of Study: Instituto Alergoimuno de Americana - São Paulo – Brazil – between January 2018 and January 2023.

Methodology: A population of 6.584 allergic patients, from which 44 (0,6%) meet the criteria for the diagnosis of SlgEd. The prevalence of the medically diagnosed allergic conditions was compared between the groups with detectable IgE and non-detectable IgE to extrapolate the Relative Risk (RR).

Results: The RR of Urticarial Vasculitis for the individuals with slgEd was 64.2 in relation to the individuals with detectable IgE. The RR of Allergic Pharyngitis for the individuals with slgEd was 2.65 in relation to the individuals with detectable IgE. The RR of Perennial Allergic Conjunctivitis for the individuals with slgEd was 2.14 in relation to the individuals with detectable IgE.

Conclusion: The comparison of the prevalence of allergic diseases among two cohorts with detectable and undetectable IgE showed a great tendency for Urticarial Vasculitis and a moderate tendency to develop Allergic Pharyngitis and Perennial Allergic Conjunctivitis among the slgEd population.

39

40

Keywords: Allergic Conjunctivitis, Allergic Pharyngitis, Allergy, Hypersensitivity, IgE, Immunodeficiency, Selective IgE Deficiency, Urticarial Vasculitis.

41

42

43

44

1. INTRODUCTION

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

The great diversity of phenotypes and endotypes of allergen-immunoreactive diseases is astonishing. A long list of conditions that affect several aspects of human physiology, through specific and nonspecific clinical presentations, in diverse graduations of severity (from the almost unperceivable immunoreactive chronic inflammatory conditions, such as gluten-related gastrointestinal disorders, to IgE-mediated life-threatening anaphylaxis) are widely grouped under the general designation of “Allergy” [1]. Although, a more technical keyword is preferred by the Medical Subject Headings of the US National Library of Medicine: “Hypersensitivity” [2]. Most of these conditions, long before the conceptualization of the participation of the immune system in allergic diseases, were studied by their organ-related symptoms, characterizing organ-specific diseases (allergic rhinitis, allergic conjunctivitis, allergic bronchitis, atopic dermatitis, eosinophilic esophagitis, etc.). Most of these diseases and syndromes are dealt with by organ-focused medical specialties, such as Dermatology, Pneumology, Otorhinolaryngology, Ophthalmology, Gastroenterology, and so on, with main attention on the control of the symptoms and the inflammation associated with their affected organs. However, the accumulation of knowledge about the immune system allowed the creation of a new medical specialty known as Allergology, which focuses on A) the diagnosis of the responsible allergens; B) the study of the immune mechanisms (Pathology); and C) their causal treatment (desensitization) [3]. However, the great complexity of the Immune System does not allow a simple and punctual interpretation of allergic diseases [4].

66 The vertebrate Immune System is primarily divided into two evolutionary arms: the
67 Innate Immune System (more ancient) and the Adaptive Immune System (more recent);
68 both can participate in allergic reactions [5]. As the Adaptive Immune System evolves from
69 and commands the Innate Immune System, this division is more evolutionary than functional
70 [6]. The Immune System can also be divided into two interactive arms: the Humoral and the
71 Cellular; both participating in allergic reactions. As the humoral compound is produced and
72 secreted by the cellular compound, this division is more morphologic/biochemical than
73 functional. The main humoral component of the Innate Immune System is the cascade of
74 proteins known as the Complement System [7]. The main humoral components of the
75 Adaptive Immune System are the several classes of antibodies (immunoglobulins).
76 Cytokines are soluble substances produced by innate and adaptive immune cells to induce
77 pro- or anti-inflammatory cellular responses and induce cellular migration (a particular subset
78 of the cytokines, called chemokines) [8]. The great majority of the immune cells belong to the
79 Innate Immune System (Macrophages, Neutrophils, Eosinophils, Basophils, Mast Cells,
80 Dendritic Cells, and so on). The main cellular components of the Adaptive Immune System
81 are the Lymphocytes, specialized in orchestrating the immune reaction (T cells) or producing
82 effector antibodies (B cells and Plasma cells). According to the involvement of the Innate,
83 Adaptive, Humoral, and Cellular arms, Gell and Coombs once classified the mechanisms of
84 hypersensitivity into four types: Type I) IgE-mediated; Type II) Antibody-dependent
85 cytotoxicity; Type III) Immune-complexes-mediated and Type IV) Cellular [9]. The last three
86 hypersensitivity reactions are also referred to as the Non—IgE-mediated allergic reactions.
87 This classification has a clinical focus, however, as these hypersensitivity mechanisms may
88 concomitantly participate in the same allergic disease, this classification may sometimes be
89 more academic than pragmatic. The inflammation produced by the allergic reactions can
90 also be classified according to the type of cytokines commanding the effector cells, such as
91 A) Type I Inflammation mediated by cytokines generated by and secreted under the
92 influence of the CD4+ T lymphocytes known as T helper 1 cell (Th1); or B) Type II
93 Inflammation, commanded by the cytokines generated by and secreted under the influence
94 of the CD4+ T lymphocytes known as T helper 2 cells (Th2). Other subsets of the Adaptive
95 response are known for their regulatory activity (Th3 and Treg) [10, 11]. The allergic
96 inflammation may be also histologically classified according to the cellular participation of the
97 compromised tissue, as it is predominantly caused by Mast cells, Basophils, Eosinophils,
98 Neutrophils, and/or Lymphocytes, for instance [12-15]. The allergen inflammation may also
99 be produced by aggregated and surmounted mechanisms such as described by the
100 Immediate-Phase Immune Response and the Late-Phase Immune Response, both
101 processed in the same location on different timelines, by different players [16]. The Innate
102 Immune System is strongly influenced by the Adaptive Immune system, as one can testify by
103 the massive presence of antibody receptors on the surface membrane of the innate immune
104 cells. Even typically effector cells, such as the neutrophils have on their surface receptors for
105 antibodies typically involved in allergic reactions, such as the IgE and the IgG [17, 18].
106 Lately, innate immune responses such as the Extracellular Nets are gaining crescent interest
107 in the study of infectious and hypersensitivity reactions [19]. The improvement of the innate
108 immune response of the allergic patient by “immune training” is a medical practice used
109 since the eighties, performed by the administration of inactivated bacterial antigens to
110 allergic patients with recurrent infections. Mechanistic studies have demonstrated that one of
111 the effects of this unspecific immunotherapy is the increase of the differentiation of
112 regulatory Lymphocytes (Treg) that produce and stimulate the production of tolerogenic
113 cytokines such as the TGF-beta, that stimulate the production of tolerogenic antibodies, such
114 as the secretory IgA, justifying the prescription of this treatment for IgE-mediated and
115 Non—IgE-mediated allergic patients [20-23].

116 Immunodeficiencies, especially the different kinds of hypo-immunoglobulin
117 syndromes, may contribute to immune dysregulation and the production of diseases. The

118 treatment of these conditions with the therapeutic administration of exogenous gamma
119 immunoglobulins may put light on the understanding of these questions, since this reposition
120 may change the profile of a Non—IgE-mediated disease to an IgE-mediated condition [24].
121 One of the more unfathomable immune conditions is familial selective IgE deficiency (slgEd)
122 [25]. The slgEd was defined for individuals able to produce, at normal amounts, all
123 antibodies' classes and subclasses, with exception of the IgE, which is not found by the
124 laboratory detection method, usually below 2.0 kIU/L [26]. This condition has also been
125 erroneously reported as “IgE hypogammaglobulinemia”, while the correct name would be
126 “hypo-immunoglobulin E syndrome”, or, maybe, “hypoepsilonglobulinemia” since the
127 “gamma immunoglobulin” is the IgG and the “epsilon immunoglobulin” is the IgE, both
128 named after their gamma and epsilon heavy chains, respectively [27, 28]. However,
129 “hypoepsilonglobulinemia” would be a weird term, since no one calls the “Hyper-IgE
130 Syndrome” like “hyperepsilonglobulinemia”. The main clinical presentations reported in
131 patients with slgEd are reactive airway diseases and skin manifestations, possibly
132 associated with the innate immune system [27, 29, 30]. The mechanisms by which the
133 slgEd cause or is associated with diseases are not elucidated, however, the slgEd may be
134 seen as a marker of immune dysregulation [26]. Naturally, patients with slgEd may present
135 concomitant diseases, which may (or not) be related to the IgE deficiency. Several reports
136 had tried to establish a statistical correlation with allergies, autoimmune diseases, and
137 tumoral diseases, however, it is difficult to differentiate the appearance of these diseases
138 from what is normally expected from the sampled population [31]. This also occurs not only
139 because the quantification of IgE is not a routine exam for most clinicians, but also, when
140 researched, the medical professionals only give credit to the augmented levels, usually
141 despising the report of an undetectable serum IgE [32].

142 The slgEd is a phenotype that deserves further studies, however, our primary
143 interest in it is to use the slgEd as a model for studying the Non—IgE-mediated allergic
144 reactions that these patients present, as well as to report the diagnosed clinical allergy
145 syndromes and the allergens associated with the symptoms as elucidated with help of the in
146 vivo tests, ex vivo challenge tests and research of precipitins.

147

148 **2. MATERIAL AND METHODS**

149

150 **2.1 Subjects**

151 After receiving Institutional Review Board approval, from the Instituto Alergoimuno de
152 Americana (Brazil), we proceed with a chart review of a population of 6.584 allergic patients,
153 from which 46 (0.7%) presented with indetectable IgE. From these, 2 also had IgA
154 deficiency, and so do not meet the criteria for the diagnosis of SlgEd. The final 44 patients
155 (0,6% of the cohort population) were diagnosed with slgEd and had their charts
156 retrospectively studied (and compared with the 6.538 patients with detectable IgE). This was
157 a very diversified cohort with 33 females; mean age 33.5 years; SD 23.9 years; range 1 to
158 85 years; mode = 1 year (appeared 6 times); geometric mean = 18.3 years.

159 **2.2 In vivo investigation**

160 All patients were submitted to immediate reading skin tests, as previously reported [33].

161 **2.3 Laboratory Investigation**

162 To evaluate the presence of elements leading to the suspect of Gell & Coombs type II and
163 type III hypersensitivity reactions we search some of the patients who had been submitted to
164 the Leukocyte Adherence Inhibition Test and the Research of Precipitins against common
165 allergens [34, 35].

166 **2.3.1 Research of tube precipitins**

167 Some patients were submitted to the research of precipitins, according to the suspected
168 allergens identified by anamnesis. The tube precipitins were researched as previously
169 described [36, 37].

170 **2.3.2 Leukocyte Adherence Inhibition Test**

171 Some patients were submitted to the Leukocyte Adherence Inhibition Test (LAIT), according
172 to the suspected allergens identified by anamnesis. The LAIT was performed as previously
173 described [38, 39].

174 **2.4 Antigen extraction**

175 Antigen extraction for the skin tests, LAIT, and the research of precipitins was performed as
176 previously described [39, 40].

177 **3. RESULTS**

178
179 Several patients presented more than one diagnosis. To present an amplified chart of
180 conditions we classified our data according to the medical diagnosis, instead of patients, to
181 show the panel of allergic diseases presented by the cohort of patients with sIgEd.

182 **3.1 Allergic Skin Tests**

183 All immediate reading allergic skin tests were “not reactive”.

184 **3.2 Urticarial vasculitis**

185 Urticarial vasculitis (UV) is a very rare condition. However, there was a disproportional
186 number of patients with this condition that also presented sIgEd. In our cohort population,
187 there were only seven patients with the diagnosis of urticarial vasculitis, out of which, two
188 presented sIgEd (28.5%). When compared with the 0.6% of sIgEd from the total cohort, it is
189 a great disparity. Among the 6.538 patients with detectable IgE, 5 had UV (0.07%). Among
190 the 44 patients with sIgEd, 2 patients had UV (4.5%). Among our population, the relative risk
191 of UV for individuals with sIgEd is 64.2 in relation to the individuals with detectable IgE.

192 **3.3 Allergic Pharyngitis**

193 Among the total enregistered population, 405 (6.1%) patients were medically diagnosed with
194 Allergic Pharyngitis (AP). Out of which, seven patients (1.7%) were medically diagnosed with
195 sIgEd; which is almost triple compared with the sIgEd proportion from the entire cohort
196 (0.6%). Among the 6.538 patients with detectable IgE, 398 had AP (6.0%). Among the 44
197 patients with sIgEd, 7 patients had AP (15.9%). Among our population, the relative risk of AP
198 for individuals with sIgEd is 2.65 in relation to the individuals with detectable IgE.

199 **3.4 Perennial Allergic Conjunctivitis**

200 Among the total enregistered population, 281 (4.2%) patients were clinically diagnosed with
201 Perennial Allergic Conjunctivitis (PAC). Out of which, four patients (1.4%) were medically
202 diagnosed with sIgEd; which is more than double when compared with the sIgEd proportion
203 from the entire cohort (0.6%). Among our population, the relative risk of PAC for the
204 individuals with sIgEd was 2.14 in relation to the individuals with detectable IgE.

205 **3.5 Other allergic conditions**

206 Besides the above, other allergic conditions diagnosed within the sIgEd group were: cow's
207 milk proteins allergy (4 cases); insect allergy (4 cases); oral allergy (1 case); intrinsic asthma
208 (5 cases); gastrointestinal allergy (5 cases); intrinsic atopic dermatitis (14 cases); contact
209 dermatitis (4 cases); intrinsic allergic rhinitis (20 cases); allergic sinusitis (1 case); and
210 chronic urticaria (5 cases).

211 **3.6 Immunoassay results**

212 As a retrospective survey, there was not a common routine laboratory investigation. Here we
213 report sparse complementary immune investigation performed in some of the cases.

214 A 49 years-old female with AP and sIgEd was investigated with the LAIT with the following
215 results: A) Airborne fungi: 70% leukocyte adherence inhibition (LAI); B) Dermatophagoides
216 pteronyssinus: 74% LAI; C) Cat dander: 74% LAI; D) Dog dander: 0% LAI; and E)
217 beekeeping pollen: 0% LAI.

218 A 59 years-old female with AP and sIgEd was investigated with the LAIT with the following
219 results: A) Dermatophagoides pteronyssinus: 76% LAI; B) Pork meat: 69% LAI; C) Cow's
220 milk: 41% LAI; D) Cocoa: 57% LAI; and E) Hevea brasiliensis latex: 36% LAI.

221 A 50 years-old female with AP and sIgEd was investigated with the LAIT with the following
222 results: A) Dermatophagoides pteronyssinus: 82% LAI; B) Airborne fungal extract: 16% LAI;
223 C) Cow's milk: 0% LAI; D) ovalbumin: 81% LAI; and E) Hevea brasiliensis latex: 0% LAI.

224 A 64 years-old female with AP, PAC, and sIgEd was investigated with the LAIT with the
225 following results: A) Dermatophagoides pteronyssinus: 61% LAI; B) Airborne fungal extract:
226 57% LAI; C) Cat dander: 84% LAI; D) Dog dander: 82% LAI; and E) beekeeping pollen: 80%
227 LAI. She was also investigated with the research of precipitins that showed positivity for: A)
228 Dermatophagoides pteronyssinus 1:128; B) Peanuts 1:64; C) Pork meat: 1:32; D) Dog
229 dander 1:128; E) Carmine cochineal extract 1:8.

230 A 1-year-old female with PAC and sIgEd was investigated with the LAIT with the following
231 results: A) Dermatophagoides pteronyssinus: 63% LAI; B) Avocado: 92% LAI; C) Banana:
232 13% LAI; D) Cocoa: 72% LAI; and E) Hevea brasiliensis latex: 38% LAI.

233

234 **4. DISCUSSION**

235

236 **4.1 Urticarial Vasculitis**

237 Urticarial Vasculitis (UV) is a rare clinicopathologic presentation of a Gell & Coombs type III
238 hypersensitivity reaction (41). Classified as a "vasculitidis": a disease produced by a
239 "vasculitis" (vascular inflammation), UV differs from the common Urticaria by the extension of
240 the vascular damage produced by the immune complexes deposition (42). Patients with UV

241 may present typical indurated wheals that disappear in less than 24 hours, however, the
242 main characteristics of the vasculitis lesions are their longer duration, the palpable purpura,
243 and the hyperpigmentation left behind (43). Diascopy is a useful method for revealing
244 inapparent purpura or hyperpigmentation occulted by the erythematous halo which
245 disappears by vitropression (44). Inflammation is the main distinction between UV and
246 Chronic Urticaria, and the quantification of the C-Reactive Protein and the Erythrocytic
247 Sedimentation Rate may be useful for differential diagnosis (45). The tissue deposition of
248 immune complexes activates the Complement cascade, consuming their components, in
249 such a way that UV may be classified as “normocomplementemic” or
250 “hypocomplementemic” (46, 47). The hypocomplementemic state may rather be reflecting
251 the activity and the severity of the disease since after the “consumption” of the serum
252 Complement components, the liver will provide the proteins to replenish systemic circulation
253 again (48). The Complement cascade originates the anaphylatoxins (C3a and C5a
254 components), that bind through specific receptors (C3aR, C5aR, and C5L2) on mast cells
255 (eliciting degranulation) and other immune cells (producing and amplifying inflammation)
256 (49). The skin biopsy typically shows a dynamic angiocentric infiltrate with leukocytoclastic
257 neutrophils (or eosinophils). There is also endothelial swelling and fibrinoid necrosis in blood
258 vessels (50). Several antigens have been associated with UV, including food allergens (51-
259 53). Antigen-Antibodies immune complexes may be assembled with any bivalent antibody,
260 including the IgE (54). At low concentrations, the immune complexes are adsorbed by the
261 red cells’ membranes and eliminated via the reticuloendothelial system (55). However, at
262 high concentrations, the immune complexes may deposit in the vascular bed, activating the
263 Complement cascade and producing inflammation and clinical symptoms, depending on the
264 affected organs, such as the cutaneous, digestive, musculoskeletal, renal, pulmonary,
265 gastrointestinal, and ocular systems (56). The digestive inflammation can aggravate the
266 intestinal hyperpermeability (leaky gut syndrome) increasing the undesirable absorption of
267 undigested proteins, producing more immune complexes, and perpetuating the disease in a
268 vicious circle (57, 58). Secondary infections may also be diagnosed in UV patients. Skin
269 infection may aggravate the inflammatory condition, turning systemic antibiotics into a
270 common first-line medication for UV patients (42). Our total cohort presented a little number
271 of patients with UV. However, among the sIgEd patients, a much greater proportion of
272 patients presented UV. Our cohort presented a relative risk of 64.2 for UV comparing
273 patients with undetectable and detectable IgE, suggesting that UV may be rather a non—IgE-
274 mediated hypersensitivity condition. Our little sample does not allow us to take statistical
275 significance from the results, but it gives us a strong suggestion about a possible relationship
276 between UV and sIgEd.

277 **4.2 Allergic Pharyngitis (AP)**

278 The pharynx is a common way for air and food. The nose-inhaled air, the mouth-inhaled air,
279 as well all the ingested food constantly in contact with the mucous membrane lining the
280 pharynx and its associated lymphatic tissue, concentrated mainly within the Waldeyer lymph
281 ring, referred to in some studies as NALT (Nose Associated Lymphoid Tissue) [57]. While
282 acute pharyngitis is more common in infancy, chronic pharyngitis is more common through
283 adulthood [58]. Several causes may be held responsible for chronic pharyngitis: acid reflux,
284 a persistent bacterial infection of the sinuses and tonsils, breathing through the mouth
285 instead of the nose, pollutants, food allergies, and allergies to inhalants [59]. Chronic
286 pharyngitis is one of the most common conditions diagnosed at ENT practice, however, the
287 diagnosis of its etiology as allergic is restrained by some issues [60]. Patients with Allergic
288 Pharyngitis (AP) complain about persistent or recurrent burning and pruritus at the
289 oropharynx [61]. To the clinical examination, they present hyperemic elevated plaques of
290 reactive lymphoid tissue in the oropharynx [62]. Allergic pharyngitis is a condition
291 recognized by the US National Library of Medicine and categorized under the code MedGen

292 UID: 664143 [63]. Recognizing that no respiratory organ is free from allergies, ENT
293 specialists also know allergic pharyngitis as “allergic chronic pharyngitis” or “allergic sore
294 throat” [64, 65]. Most of our patients diagnosed with AP also presented occasional episodes
295 of acute laryngitis, with hoarseness, hacking cough, inspiratory dyspnea, and paradoxical
296 vocal fold motion demonstrated by the nasal allergen challenge monitored by spirometry
297 [66]. AP is a condition usually diagnosed only by doctors with personal experience with its
298 symptoms since the absence of unified diagnostic standards, treatment guidelines, and
299 epidemiological data, produces a poor awareness of the condition, mainly when the
300 oropharynx is not the main anatomical site of the symptoms [67]. However, when actively
301 researched through anamnesis and a detailed physical examination, the number of patients
302 with this diagnosis progressively increases in daily clinical practice. When the
303 hypersensitivity is IgE-mediated, the relationship between chronic pharyngitis and allergies is
304 easier to establish. However, the diagnosis of a non—IgE-mediated hypersensitivity is much
305 more difficult to demonstrate. Our cohort presented a relative risk of 2.65 for AP comparing
306 patients with undetectable and detectable IgE, suggesting that AP may be rather a non—IgE-
307 mediated hypersensitivity condition.

308 **4.3 Perennial Allergic Conjunctivitis**

309 Allergic Conjunctivitis is a condition caused by the conjunctival inflammatory response to
310 specific allergens [68]. Allergic Conjunctivitis has been classified by different authors, in
311 different ways, according to their experience, resources, and current understanding of the
312 immunologic mechanisms behind the disease’s physiopathology [69]. Anamnesis is a simple
313 way to first classify ocular allergies as seasonal or perennial, according to the persistence of
314 the symptoms. The second pass to classify ocular allergies is the ophthalmic examination,
315 which will determine the sole involvement of the conjunctive, or a concomitant corneal and/or
316 palpebral commitment. The prevailing laboratory resource for the practical allergist is
317 currently specific IgE research. Hence, the third pass is to classify the ocular allergy as IgE-
318 mediated (Gell & Coombs type I) or non—IgE-mediated hypersensitivity. This is a simplistic
319 classification, and one must also consider mixed conditions, where IgE-mediated and non-
320 IgE-mediated mechanisms participate together. The typical ocular Gell & Coombs type I
321 hypersensitivity reaction is Seasonal Allergic Conjunctivitis, an immediate (acute) response
322 produced after the degranulation of histamine from the conjunctival Mast Cells, elicited by
323 the cross-linking of surface IgE bound to allergens. Less frequent, there is Perennial Allergic
324 Conjunctivitis (PAC), which may be (or not) elicited by IgE-mediated mechanisms but is
325 maintained as chronic conjunctival inflammation, as described by the Gell & Coombs type II
326 hypersensitivity reaction, characterized by the infiltration of neutrophils, eosinophils and T
327 cells responsible for the release of proinflammatory cytokines [70]. Our cohort presented a
328 relative risk of 2.14 for PAC comparing patients with undetectable and detectable IgE,
329 suggesting that the IgE is not a predominant participant in this condition.

330 **4.4 Selective IgE deficiency (sIgEd)**

331 Familial sIgEd has not yet had the official status of a Primary Immunodeficiency. Broader
332 studies are in need to be planned and executed to understand the pathophysiology of
333 diseases produced or influenced by this condition, especially allergic ones. This particularity
334 resides in the fact that normal IgE-producers and hyper IgE-producers may present the
335 same conditions found in patients with sIgEd. Additionally, there is no clear physiopathologic
336 mechanism able to explain a link between sIgEd and any disease since there is no animal
337 model to study this condition. Most physicians simply don’t pay attention to a result of
338 undetectable IgE, just considering it a negative result inside the context of the triage of
339 allergic diseases. As most studies are performed retrospectively, if the physician doesn’t
340 register this detail, the diagnosis must be lost, turning impossible to compare the clinical

341 characteristics of populations with and without the capacity to produce IgE. At our outpatient
342 facility, the diagnosis of sIgEd is a concern in the investigation of allergic symptoms, and a
343 comparative study is possible, based on the two cohort populations. The increase of the
344 relative risk for AF and PAC, comparing the IgE-producers' cohort with the Non—IgE-
345 producers' cohort is not quite representative information when considering the low number of
346 subjects, but represents a clue for more detailed investigations. However, what called our
347 attention was the disproportional number of patients with UV inside the group with sIgEd.
348 The reason for that eludes our understanding. Maybe some multiligand superantigen or
349 superallergen like an IgE-specific Cross-Reactive Carbohydrate Determinant (CCD) or an
350 IgE-specific "protein Fv", sequestering all the circulating IgE into the assemblage of the
351 immune complexes [71]? This is just speculation. The appearance of antibodies against
352 CCD is a phenomenon taken into account to dismiss false-positive reactions inside the
353 laboratory investigation of IgE-mediated hypersensitivity diseases [72]. The CCDs are
354 immunogenic glycoproteins that can cross-react with antibodies directed against diverse
355 allergens. Glycoproteins were already described to produce severe Non—IgE-mediated
356 delayed anaphylaxis [73]. Would these multiligand superallergens be acquired to blood
357 circulation through a highly permeable leaky gut [74]? More studies, with a larger number of
358 patients, must be done to answer these questions.

359

360 **5. CONCLUSION**

361

362 The comparison of the prevalence of allergic diseases among two cohorts with detectable
363 and undetectable IgE showed a great tendency for Urticarial Vasculitis and a moderate
364 tendency to develop Allergic Pharyngitis and Perennial Allergic Conjunctivitis among the
365 sIgEd population.

CONSENT

386 As a retrospective chart review with anonymous data, without any human experimentation,
387 this section is not applicable, in accordance with the 1964 Declaration of Helsinki.

388

ETHICAL APPROVAL

389

390
391 As a retrospective chart review with anonymous data, without any human experimentation,
392 this section was not applicable, in accordance with the 1964 Declaration of Helsinki.

393

394

395

REFERENCES

396

397
398 1. Holgate ST, Church M. Allergy. London and New York: Gower Medical Publishing
399 Ltd.; 1993.

400 2. US National Library of Medicine: "Hypersensitivity" Bethesda, Maryland: US National
401 Institutes of Health; 2023 [Available from: <https://id.nlm.nih.gov/mesh/D006967.html>].

402 3. Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. *Curr Opin*
403 *Immunol.* 2006;18(6):718-26.

404 4. Oettgen H, Broide DH, Holgate ST, Church MK, Martinez FD. Introduction to
405 mechanisms of allergic disease. In: Elsevier, editor. *Allergy* (Fourth Edition). Edinburgh:
406 W.B. Saunders; 2012. p. 1-32.

407 5. Chaplin DD. 1. Overview of the immune response. *JACI.* 2003;111(2, Supplement
408 2):S442-S59.

409 6. Netea Mihai G, Quintin J, van der Meer Jos WM. Trained Immunity: A Memory for
410 Innate Host Defense. *Cell Host & Microbe.* 2011;9(5):355-61.

411 7. Carroll Michael C, Isenman David E. Regulation of Humoral Immunity by
412 Complement. *Immunity.* 2012;37(2):199-207.

413 8. Borish LC, Steinke JW. 2. Cytokines and chemokines. *J Allergy Clin Immunol.*
414 2003;111(2 Suppl):S460-75.

- 415 9. Gell PGH, Coombs RRA. Classification of Allergic Reactions Responsible for
416 Clinical Hypersensitivity and Disease. In: Gell PGH, Coombs RRA, editors. *Clinical Aspects*
417 *of Immunology*. 2nd ed. Oxford: Blackwell Scientific Publications; 1968. p. 575-96.
- 418 10. Carrier Y, Yuan J, Kuchroo VK, Weiner HL. Th3 cells in peripheral tolerance. I.
419 Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-
420 transgenic mice. *J Immunol*. 2007;178(1):179-85.
- 421 11. Caridade M, Graca L, Ribeiro RM. Mechanisms underlying CD4+ Treg immune
422 regulation in the adult: from experiments to models. *Frontiers in Immunology*. 2013;4.
- 423 12. Park HS, Kim HS, Jang HJ. Eosinophilic gastroenteritis associated with food allergy
424 and bronchial asthma. *J Korean Med Sci*. 1995;10(3):216-9.
- 425 13. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. *The*
426 *Journal of allergy and clinical immunology*. 2010;125(2 Suppl 2):S73-S80.
- 427 14. Cotta AC, Cintra ML, Souza EMD, Magna LA, Vassallo J. Reassessment of
428 diagnostic criteria in cutaneous lymphocytic infiltrates. *Sao Paulo Medical Journal*.
429 2004;122(4):161-5.
- 430 15. Rodriguez-Rosales YA, Langereis JD, Gorris MAJ, van den Reek JMPA, Fasse E,
431 Netea MG, et al. Immunomodulatory aged neutrophils are augmented in blood and skin of
432 psoriasis patients. *Journal of Allergy and Clinical Immunology*. 2021;148(4):1030-40.
- 433 16. Miyahara S, Miyahara N, Lucas JJ, Joetham A, Matsubara S, Ohnishi H, et al.
434 Contribution of allergen-specific and nonspecific nasal responses to early-phase and late-
435 phase nasal responses. *J Allergy Clin Immunol*. 2008;121(3):718-24.
- 436 17. Jonsson F, de Chaisemartin L, Granger V, Gouel-Cheron A, Gillis CM, Zhu Q, et al.
437 An IgG-induced neutrophil activation pathway contributes to human drug-induced
438 anaphylaxis. *Sci Transl Med*.11(500).
- 439 18. Truong MJ, Gruart V, Kusnierz JP, Papin JP, Loiseau S, Capron A, et al. Human
440 neutrophils express immunoglobulin E (IgE)-binding proteins (Mac-2/epsilon BP) of the S-
441 type lectin family: role in IgE-dependent activation. *J Exp Med*. 1993;177(1):243-8.
- 442 19. Bailo G, Rodríguez FM, Carabajal-Miotti CL, Frattari SGR, Vargas AH, González-
443 Silva NE, et al. Influence of Extracellular Traps (ETs) on the Differentiation of TCD4 Cell
444 Profiles and Macrophages in Human Autologous Culture. *European Journal of Clinical*
445 *Medicine*. 2023;4(1):14-22.
- 446 20. Troy NM, Strickland D, Serralha M, de Jong E, Jones AC, Read J, et al. Protection
447 against severe infant lower respiratory tract infections by immune training: Mechanistic
448 studies. *J Allergy Clin Immunol*. 2022;150(1):93-103.
- 449 21. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen K-L, Schaad UB.
450 Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and
451 asthma in children: a systematic review of mechanistic and clinical evidence. *Curr Opin*
452 *Allergy Clin Immunol*. 2018;18(3).

- 453 22. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C.
454 Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-
455 cell tolerance, and immune deviation. *J Allergy Clin Immunol.* 2007;120(3):707-13.
- 456 23. Bohle B. Immunological mechanisms in sublingual immunotherapy. *Drugs Today*
457 (Barc). 2008;44 Suppl B:95-6.
- 458 24. Raham TF. A Case Report and Review of Increased IgE in Patients with Transient
459 Hypogammaglobulinemia of Infancy and Atopic Dermatitis after Normalization of IgG. *Asian*
460 *J Ped Res.* 2023;11(2):25-32.
- 461 25. Schoettler JJ, Schleissner LA, Heiner DC. Familial IgE deficiency associated with
462 sinopulmonary disease. *Chest.* 1989;96(3):516-21.
- 463 26. Magen E, Schlesinger M, David M, Ben-Zion I, Vardy D. Selective IgE deficiency,
464 immune dysregulation, and autoimmunity. *Allergy Asthma Proc.* 2014;35(2):e27-33.
- 465 27. Smith JK, Krishnaswamy GH, Dykes R, Reynolds S, Berk SL. Clinical
466 manifestations of IgE hypogammaglobulinemia. *Ann Allergy Asthma Immunol.*
467 1997;78(3):313-8.
- 468 28. Schroeder HW, Jr., Cavacini L. Structure and function of immunoglobulins. *J Allergy*
469 *Clin Immunol.* 2010;125(2 Suppl 2):S41-52.
- 470 29. Levin TA, Ownby DR, Smith PH, Peterson EL, Williams LK, Ford J, et al.
471 Relationship between extremely low total serum IgE levels and rhinosinusitis. *Ann Allergy*
472 *Asthma Immunol.* 2006;97(5):650-2.
- 473 30. Picado C, García-Herrera AP, Hernández-Rodríguez J, Vlajea A, Pascal M, Bartra J,
474 et al. Skin Manifestations in Patients with Selective Immunoglobulin E Deficiency. *Journal of*
475 *clinical medicine [Internet].* 2022; 11(22).
- 476 31. Picado C, Ortiz de Landazuri I, Vlajea A, Bobolea I, Arismendi E, Amaro R, et al.
477 Spectrum of Disease Manifestations in Patients with Selective Immunoglobulin E Deficiency.
478 *Journal of clinical medicine [Internet].* 2021; 10(18).
- 479 32. Çildağ S, Şentürk T, Sargin G. Hypoglobulinemia Frequency in Adult Patients with
480 Allergic Rhinitis. *World Clin J Med Sci.* 2017;1(1):1-4.
- 481 33. Olivier CE, Argentão DGP, Santos RAPG, Silva MD, Lima RPS, Zollner RL. Skin
482 scrape test: an inexpensive and painless skin test for recognition of immediate
483 hypersensitivity in children and adults. *The Open Allergy Journal.* 2013;6:9-17.
- 484 34. Olivier CE, Lima RPdS, Pinto DG, Santos RAPGd. The Plasma Preincubation with
485 Papain Before the Assay Suggests that a Gell and Coombs Type II Reaction is Been
486 Demonstrated by the Leukocyte Adherence Inhibition Test. *Biomedical Journal of Scientific*
487 *& Technical Research.* 2021;36(3):28647 - 55.
- 488 35. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS.
489 Intrinsic Atopic Dermatitis: Titration of Precipitins in the Screening of Food Allergens for
490 Prescription of Elimination Diets and Desensitization Strategies. *Eur J Clin Med.* 2021;2(6):1-
491 9.

- 492 36. Olivier CE, Pinto DG, Lima RPdS, Teixeira APM, Santana JLS. Self-imposed food
493 restriction and oral food challenges are correlated with precipitin's accuracy in the diagnosis
494 of non-IgE-mediated food-related adulthood acute episodes of urticaria. *Journal of Allergy &*
495 *Therapy*. 2021;12(8):1-8.
- 496 37. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Anti-
497 *Saccharomyces cerevisiae* antibodies (ASCA) researched by tube precipitins are elevated in
498 patients with dermatologic and gastrointestinal non—IgE-mediated hypersensitivity.
499 *European Journal of Clinical Medicine*. 2023;4(2):25-30.
- 500 38. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS.
501 Contribution of the Leukocyte Adherence Inhibition Test for the evaluation of
502 immunoreactivity against gluten extracts in non—IgE-mediated / non-autoimmune Gluten-
503 Related Disorders. *European Journal of Clinical Medicine*. 2022;3(2):1-7.
- 504 39. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al.
505 Evaluating Non-IgE-Mediated Allergens' Immunoreactivity in Patients Formerly Classified as
506 "Intrinsic" Asthmatics with Help of the Leukocyte Adherence Inhibition Test. *European*
507 *Journal of Clinical Medicine*. 2023;4(2):1-7.
- 508 40. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al.
509 Evaluating Non-IgE-mediated Allergens' Immunoreactivity in Patients with "Intrinsic"
510 Persistent Rhinitis with Help of the Leukocyte Adherence Inhibition Test. *European Journal*
511 *of Medical and Health Sciences*. 2023;5(1):17-22.
- 512 41. Mehregan DR, Gibson LE. Pathophysiology of urticarial vasculitis. *Arch Dermatol*.
513 1998;134(1):88-9.
- 514 42. Gu SL, Jorizzo JL. Urticarial vasculitis. *International journal of women's dermatology*.
515 2021;7(3):290-7.
- 516 43. Lee JSS, Loh TH, Seow SC, Tan SH. Prolonged urticaria with purpura: The
517 spectrum of clinical and histopathologic features in a prospective series of 22 patients
518 exhibiting the clinical features of urticarial vasculitis. *J Am Acad Dermatol*. 2007;56(6):994-
519 1005.
- 520 44. Dahl MV. Clinical Pearl: Diascopy helps diagnose urticarial vasculitis. *Journal of the*
521 *American Academy of Dermatology*. 1994;30(3):481-2.
- 522 45. Kolkhir P, Bonnekoh H, Kocatürk E, Hide M, Metz M, Sánchez-Borges M, et al.
523 Management of urticarial vasculitis: A worldwide physician perspective. *World Allergy*
524 *Organization Journal*. 2020;13(3):100107.
- 525 46. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Saavedra MA. Hypocomplementemic
526 urticarial vasculitis syndrome. *Current rheumatology reports*. 2009;11(6):410-5.
- 527 47. Gökçe Ş, Dörtkardeşler BE, Aslan A. Normocomplementemic Urticarial Vasculitis
528 Associated with A/H1N1 in a Child. Case Report. *SN comprehensive clinical medicine*.
529 2020;2(12):2962-4.
- 530 48. Damman J, Mooyaart AL, Seelen MAJ, van Doorn MBA. Dermal C4d Deposition
531 and Neutrophil Alignment Along the Dermal–Epidermal Junction as a Diagnostic Adjunct for

- 532 Hypocomplementemic Urticarial Vasculitis (Anti-C1q Vasculitis) and Underlying Systemic
533 Disease. *Amer J Dermatopathol.* 2020;42(6):399-406.
- 534 49. Peng Q, Li K, Sacks HS, Zhou W. The Role of Anaphylatoxins C3a and C5a in
535 Regulating Innate and Adaptive Immune Responses. *Inflammation & Allergy - Drug Targets.*
536 2009;8(3):236-46.
- 537 50. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis. Serial
538 histopathologic evaluation demonstrates the dynamic nature of the infiltrate. *Arch Dermatol.*
539 1990;126(1):69-72.
- 540 51. Businco L, Falconieri P, Bellioni-Businco B, Bahna SL. Severe food-induced
541 vasculitis in two children. *Pediatric Allergy and Immunology.* 2002;13(1):68-71.
- 542 52. Eisenmann A, Ring J, von der Helm D, Meurer M, Braun-Falco O. [Allergic vasculitis
543 caused by food allergy]. *Hautarzt (Die Dermatologie).* 1988;39(5):318-21.
- 544 53. Lefvert AK. Recurrent angioedema caused by circulating immune complexes
545 containing antibodies against bovine proteins. *Int Arch Allergy Immunol.* 1993;102(1):112-6.
- 546 54. Zuberi RI, Apgar JR, Chen S-S, Liu F-T. Role for IgE in Airway Secretions: IgE
547 Immune Complexes Are More Potent Inducers Than Antigen Alone of Airway Inflammation
548 in a Murine Model. *J Immunol.* 2000;164(5):2667-73.
- 549 55. Saba TM. Physiology and Physiopathology of the Reticuloendothelial System. *Arch*
550 *Internal Med.* 1970;126(6):1031-52.
- 551 56. Grotz W, Baba HA, Becker JU, Baumgärtel MW. Hypocomplementemic urticarial
552 vasculitis syndrome: an interdisciplinary challenge. *Deutsches Arzteblatt international.*
553 2009;106(46):756-63.
- 554 57. Pantic I, Jevtic D, Nordstrom CW, Madrid C, Milovanovic T, Dumic I. Clinical
555 Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with
556 Ulcerative Colitis: A Systematic Review of the Literature. *Journal of clinical medicine.*
557 2022;11(3).
- 558 58. Olivier CE. Considering intestinal permeability and immune metabolism in the
559 treatment of food allergies. *Eur J Clin Med.* 2022;3(3):13-8.
- 560 59. M. M, J. K, E. Z, G. P. [The allergic pharyngitis]. *Medycyna Rodzinna.* 2003;6:199-
561 202.
- 562 60. Stephenson KN. Acute and chronic pharyngitis across the lifespan. *Lippincotts Prim*
563 *Care Pract.* 2000;4(5):471-89.
- 564 61. Sibanda EN. Inhalant Allergies in Zimbabwe: A Common Problem. *International*
565 *Archives of Allergy and Immunology.* 2003;130(1):2-9.
- 566 62. Pukhlik S, A. S. Diagnostic issues of allergic pharyngitis. *Balneo Res J.*
567 2020;11(2):149-53.
- 568 63. Li Z, Huang J, Hu Z. Screening and Diagnosis of Chronic Pharyngitis Based on
569 Deep Learning. *Int J Environ Res Public Health.* 2019;16(10).

- 570 64. Hollender AR. Hypertrophy of the lingual tonsil and lymphoid tissue of the pharynx;
571 Reduction by electro-coagulation. *The Laryngoscope*. 1932;42(8):622-6.
- 572 65. US National Library of Medicine: Allergic pharyngitis (MedGen UID: 664143).
573 Bethesda, Maryland: US National Institutes of Health; 2023 [Available from:
574 <https://www.ncbi.nlm.nih.gov/medgen/?term=664143>.
- 575 66. Pulec JL. Allergy in Otolaryngology. *Ear, Nose & Throat J*. 1994;73(4):209-.
- 576 67. Filou M, Revel S, Le Guillou F. [Chronic allergic pharyngitis]. *La Presse thermale et*
577 *climatique*. 1967;104(3):126-7.
- 578 68. Olivier CE, Argentao DG, Lima RP, da Silva MD, Dos Santos RA. The nasal
579 provocation test combined with spirometry establishes paradoxical vocal fold motion in
580 allergic subjects. *Allergy Asthma Proc*. 2013;34(5):453-8.
- 581 69. Liu J, Yan Z, Zhang M. [Clinical diagnosis and treatment of allergic pharyngitis]. *Lin*
582 *chuang er bi yan hou tou jing wai ke za zhi* = *Journal of clinical otorhinolaryngology, head,*
583 *and neck surgery*. 2015;29(15):1401-5.
- 584 70. Villegas BV, Benitez-Del-Castillo JM. Current Knowledge in Allergic Conjunctivitis.
585 *Turkish journal of ophthalmology*. 2021;51(1):45-54.
- 586 71. Friedlaender MH. Ocular allergy. *Current opinion in allergy and clinical immunology*.
587 2011;11(5):477-82.
- 588 72. Hingorani M, L. CV, L. B, S. L. Allergic conjunctivitis. In: Holgate ST, Church M. K.,
589 Broide D. H. and Martinez F. D., editor. *Allergy*. 4° ed: Elsevier; 2012. p. 225-46.
- 590 73. Bouvet J, Marone G. Protein Fv: An Endogenous Immunoglobulin Superantigen and
591 Superallergen. *Chem Immunol Allergy*. 2007;93:58-76.
- 592 74. M. AD, R. FLG, A. P-R, R. B-BM, L. ZR. Cross-Reactive Carbohydrate Determinant
593 in *Apis mellifera*, *Solenopsis invicta* and *Polybia paulista* Venoms: Identification of Allergic
594 Sensitization and Cross-Reactivity. *Toxins*. 2020;12(649):1-18.
- 595 75. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewis BD, et al. Delayed
596 anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE
597 antibodies specific for galactose-alpha-1,3-galactose. *J Allergy Clin Immunol*.
598 2009;123(2):426-33.
- 599